181 related articles for article (PubMed ID: 35611637)
1. Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons.
Xu D; Yu F; Guo T; Zhou Y; Zhang J; Li Y; Jiang S; Mao J; Yang X; Chu L; Chu X; Wang S; Ni J; Zhu Z
Br J Radiol; 2022 Aug; 95(1136):20220035. PubMed ID: 35611637
[TBL] [Abstract][Full Text] [Related]
2. Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor.
Ng TL; Morgan RL; Patil T; Barón AE; Smith DE; Ross Camidge D
Lung Cancer; 2018 Dec; 126():112-118. PubMed ID: 30527174
[TBL] [Abstract][Full Text] [Related]
3. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
Jiang T; Chu Q; Wang H; Zhou F; Gao G; Chen X; Li X; Zhao C; Xu Q; Li W; Wu F; Xiong A; Zhao J; Xu Y; Su C; Ren S; Zhou C; Hirsch FR
Int J Cancer; 2019 May; 144(10):2605-2612. PubMed ID: 30387880
[TBL] [Abstract][Full Text] [Related]
4. Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
Schuler A; Huser J; Schmid S; Schär S; Scherz A; Gautschi O; Mauti L; von Briel T; Waibel C; Wannesson L; Pankovics J; Mark MT; Rothschild SI; Addeo A; Janthur WD; Siano M; Boos L; Britschgi C; Früh M
Lung Cancer; 2024 Jan; 187():107427. PubMed ID: 38043395
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
6. Value of interim
Shao D; Cheng Y; Yuan ZS; Jiang BY; Wang SX
Lung Cancer; 2020 Nov; 149():137-143. PubMed ID: 33011375
[TBL] [Abstract][Full Text] [Related]
7. A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Lu CF; Liao CY; Chao HS; Chiu HY; Wang TW; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
Cancer Imaging; 2023 Jan; 23(1):9. PubMed ID: 36670497
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
[TBL] [Abstract][Full Text] [Related]
9. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
[TBL] [Abstract][Full Text] [Related]
10. Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study.
Ni Y; Bi J; Ye X; Fan W; Yu G; Yang X; Huang G; Li W; Wang J; Han X; Ni X; Wei Z; Han M; Zheng A; Meng M; Xue G; Zhang L; Wan C
Medicine (Baltimore); 2016 Jun; 95(25):e3998. PubMed ID: 27336903
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study.
Wei H; Zhou X; Yang H; Gong Y; Wang J; Xu Y; Zhou L; Xue J; Zou B; Zhang Y; Zhu J; Peng F; Huang M; Lu Y; Liu Y
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2589-2598. PubMed ID: 34669037
[TBL] [Abstract][Full Text] [Related]
12. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
Su PL; Chen CW; Wu YL; Lin CC; Su WC
Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
[TBL] [Abstract][Full Text] [Related]
14. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
15. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
[TBL] [Abstract][Full Text] [Related]
16. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.
Nishino M; Cardarella S; Dahlberg SE; Jackman DM; Ramaiya NH; Hatabu H; Rabin MS; Jänne PA; Johnson BE
Lung Cancer; 2013 Mar; 79(3):283-8. PubMed ID: 23254265
[TBL] [Abstract][Full Text] [Related]
17. Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.
Hong SH; Kim YS; Lee JE; Kim IH; Kim SJ; Han D; Yoo IeR; Chung YG; Kim YH; Lee KY; Kang JH
Cancer Res Treat; 2016 Jul; 48(3):1110-9. PubMed ID: 26790969
[TBL] [Abstract][Full Text] [Related]
18. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
19. Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease.
Ni Y; Liu B; Ye X; Fan W; Bi J; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
Cardiovasc Intervent Radiol; 2019 May; 42(5):693-699. PubMed ID: 30701290
[TBL] [Abstract][Full Text] [Related]
20. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management.
Sun X; Xiao Z; Chen G; Han Z; Liu Y; Zhang C; Sun Y; Song Y; Wang K; Fang F; Wang X; Lin Y; Xu L; Shao L; Li J; Cheng Z; Gambhir SS; Shen B
Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29515002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]